Summary of LB Pharmaceuticals Conference Call Company Overview - LB Pharmaceuticals is positioned well with a steady stream of clinically meaningful value-creating catalysts, including: - Phase 3 schizophrenia data expected in the second half of 2027 - Phase 2 bipolar depression data expected in the first quarter of 2028 - Adjunctive major depressive disorder (MDD) data expected in the first half of 2029 - The late-stage asset, LB-102, is anticipated to have a differentiated profile in the branded antipsychotic market [2][3] Key Points on Clinical Trials - **Phase 2 Trial Design**: - Conducted with 359 patients across 25 sites in the U.S. - Designed to be registrational, with a robust effect size ranging from 0.5 to 0.6 [10] - **Phase 3 Trial Design**: - Will include two doses (50 mg and 100 mg) and a three-arm trial structure to manage placebo rates [4][5] - Incorporates measures from Phase 2 to mitigate risks, including central raters and vendor support to exclude professional patients [5][8] - Duration extended from 4 weeks in Phase 2 to 6 weeks in Phase 3 to enhance data robustness [10] Market Positioning and Competitive Landscape - LB-102 is expected to differentiate itself from competitors like Cobenfy, which has dosing challenges and side effects [12][15] - The drug is positioned to treat acute exacerbations of schizophrenia with a favorable tolerability profile, potentially becoming the branded antipsychotic of choice [15][16] - The company believes that the launch of LB-102 could be more successful than Cobenfy due to its rapid onset of action and lack of titration requirements [12][15] Bipolar Depression and MDD Insights - While specific data for LB-102 in bipolar depression is lacking, the company believes that the biological underpinnings of depression are similar across major depression and bipolar depression [18][20] - A fixed flexible dose design is planned for bipolar depression trials, starting at 25 mg and escalating to 50 mg [20][21] - The company is confident in its dosing strategy for adjunctive MDD, with doses of 15 mg and 25 mg being evaluated [58][59] Safety and Tolerability Profile - LB-102 demonstrated a low rate of extrapyramidal symptoms (EPS) in Phase 2 trials, with only one case at 50 mg and two cases at 100 mg, which is lower than placebo [44][45] - The drug shows negligible sedation compared to competitors, which is advantageous for patients in mood disorder treatments [45][46] - The company aims to maintain a favorable safety profile while addressing residual symptoms like cognitive impairment and anhedonia [39][41] Financial Position and Future Outlook - The recent financing provides cash runway into the second quarter of 2029, fully funding all discussed trials and enabling studies [66][68] - The company is focused on executing its clinical trials and is well-capitalized to pursue regulatory approvals if Phase 3 trials are successful [68] Conclusion - LB Pharmaceuticals is strategically positioned with a robust pipeline and a focus on differentiating its product, LB-102, in the competitive landscape of antipsychotic medications. The company is confident in its clinical trial designs and safety profiles, aiming for successful outcomes in schizophrenia, bipolar depression, and MDD indications.

Financial Data and Key Metrics Changes - For fiscal year 2025, net revenue was $66.4 million, a slight increase from $65.2 million in the previous year [27] - Adjusted EBITDA for the year was $9.2 million, marking the third consecutive year of positive adjusted EBITDA, compared to $10.8 million in the prior year [32] - Gross margin decreased to 69% from 75% in the previous year, primarily due to increased cost of sales in ADHD inventory [28][29] Business Line Data and Key Metrics Changes - ADHD portfolio net revenue was $57.6 million, down from $57.8 million, attributed to a decrease in the number of prescriptions written [27] - Pediatric portfolio revenue increased to $8.8 million from $7.3 million, reflecting a successful return-to-growth plan [28] Market Data and Key Metrics Changes - The U.S. market for major depressive disorder (MDD) is over $22 billion, with Exua targeting a significant portion of this market [7][9] - SSRIs and SNRIs represent over 60% of all antidepressants prescribed, indicating a competitive landscape for Exua [9][10] Company Strategy and Development Direction - The company is focusing on the launch of Exua, a novel treatment for MDD, which is expected to transform its business model [4][7] - Aytu BioPharma plans to leverage its psychiatry-focused sales force and proprietary Aytu RxConnect platform for the launch of Exua [6][14] - The company aims to maintain market share in the ADHD segment despite the entry of generics by launching an authorized generic of Adzenys [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming launch of Exua and its potential to address unmet needs in the MDD market [4][11] - The company anticipates a positive trajectory for Exua as it ramps up commercial efforts, expecting to exit fiscal 2026 as one of the fastest-growing CNS-focused companies [42] Other Important Information - The company has successfully raised $16.6 million through a public offering to support the Exua launch [34] - Aytu BioPharma has restructured its operations, resulting in a new cost structure that projects a break-even level of approximately $52.6 million annually [30] Q&A Session Summary Question: Will there be a national sales meeting for Exua? - Management confirmed that a sales meeting is planned before the full launch in the first calendar quarter of 2026 [45] Question: Will promotional materials be pre-cleared? - Management stated they do not plan to pre-clear promotional materials but will follow the traditional submission process [46] Question: What is the strategy for engaging with payers? - Management indicated a selective approach to payer engagement, focusing on government payers due to favorable coverage for MDD [50][52] Question: What are the expectations for the ADHD and pediatric franchises? - Management expects the ADHD and pediatric portfolios to cover general and administrative expenses, with a focus on maintaining margin positivity [58][60] Question: What is the plan for medical affairs and education for Exua? - Management outlined extensive efforts in medical affairs, including engagement with key opinion leaders and participation in medical conferences [61]

Financial Data and Key Metrics Changes - For fiscal year 2025, net revenue was $66.4 million, a slight increase from $65.2 million in the previous year [28] - Adjusted EBITDA for the year was $9.2 million, marking the third consecutive year of positive adjusted EBITDA [34] - The net loss for the year was $13.6 million, an improvement from a net loss of $15.8 million in the prior year [32] Business Line Data and Key Metrics Changes - ADHD portfolio net revenue was $57.6 million, down from $57.8 million, attributed to a decrease in the number of prescriptions written [28] - Pediatric portfolio revenue increased to $8.8 million from $7.3 million, reflecting a successful return-to-growth plan [29] - Gross margin decreased to 69% from 75%, primarily due to increased cost of sales in ADHD inventory [29] Market Data and Key Metrics Changes - The U.S. market for major depressive disorder (MDD) is over $22 billion, with more than 340 million prescriptions written annually [9] - SSRIs and SNRIs account for approximately 220 million TRXs, representing over 60% of all antidepressants prescribed [9] Company Strategy and Development Direction - The company is focusing on the upcoming launch of Exua, a novel treatment for MDD, which is expected to transform its business [4][7] - Aytu BioPharma plans to leverage its psychiatry-focused sales force and proprietary Aytu RxConnect patient access platform for product acquisitions aligned with its focus [6] - The company aims to minimize coverage barriers and enhance patient access through selective payer contracting [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the Exua launch, highlighting positive feedback from psychiatrists regarding the product's potential [41][43] - The company anticipates that the Exua opportunity will significantly enhance its growth trajectory, positioning it as a leading CNS-focused company [44] Other Important Information - The company has successfully completed a public offering totaling $16.6 million gross, which is seen as validation of the Exua opportunity [35] - Aytu BioPharma has launched an authorized generic of Adzenys to maintain market share amid potential competition from Teva [21] Q&A Session Summary Question: Will there be a national sales meeting for Exua? - Management confirmed that a sales meeting is expected before the full launch in the first calendar quarter of 2026 [47] Question: Will promotional materials be pre-cleared? - Management stated they do not plan to pre-clear promotional materials, citing confidence in their compliant promotional platform [48] Question: What is the plan for engaging with payers? - Management indicated a selective approach to payer engagement, focusing on ensuring favorable contracting without undermining margins [52][54] Question: What are the expectations for the ADHD and pediatric franchises? - Management expects the ADHD and pediatric portfolios to cover general and administrative expenses, with a focus on maintaining margin positivity [60][62] Question: What is the medical affairs strategy for Exua? - Management outlined an extensive medical affairs effort, including engagement with key opinion leaders and participation in medical conferences [63]